Sandro Gentile

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6730715/publications.pdf

Version: 2024-02-01

567281 454955 37 935 15 30 citations h-index g-index papers 38 38 38 1190 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comment on the article Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes. Endocrinologia, Diabetes Y NutriciÓn, 2022, , .	0.3	O
2	The Economic Burden of Insulin Injection-Induced Lipohypertophy. Role of Education: The ISTERP-3 Study. Advances in Therapy, 2022, 39, 2192-2207.	2.9	8
3	Comparison between Policaptil Gel Retard and Metformin by Testing of Temporal Changes in Patients with Metabolic Syndrome and Type 2 Diabetes. International Journal of Diabetology, 2022, 3, 315-327.	2.0	1
4	Lipohypertrophy in Elderly Insulin-Treated Patients With Type 2 Diabetes. Diabetes Therapy, 2021, 12, 107-119.	2.5	10
5	Role of Structured Education in Reducing Lypodistrophy and its Metabolic Complications in Insulin-Treated People with Type 2 Diabetes: A Randomized Multicenter Case–Control Study. Diabetes Therapy, 2021, 12, 1379-1398.	2.5	15
6	Bruising: A Neglected, Though Patient-Relevant Complication of Insulin Injections Coming to Light from a Real-Life Nationwide Survey. Diabetes Therapy, 2021, 12, 1143-1157.	2.5	7
7	Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis. Advances in Therapy, 2021, 38, 4195-4214.	2.9	3
8	Insulin-induced skin lipohypertrophies: A neglected cause of hypoglycemia in dialysed individuals with diabetes. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 102145.	3.6	0
9	The Durability of an Intensive, Structured Education-Based Rehabilitation Protocol for Best Insulin Injection Practice: The ISTERP-2 Study. Diabetes Therapy, 2021, 12, 2557-2569.	2.5	13
10	Hundred-year experience with insulin and lipohypertrophy: An unresolved issue. Diabetes Research and Clinical Practice, 2021, 178, 108924.	2.8	1
11	Insulin-Induced Skin Lipohypertrophy in Type 2 Diabetes: a Multicenter Regional Survey in Southern Italy. Diabetes Therapy, 2020, 11, 2001-2017.	2.5	29
12	<scp>COVID</scp> â€19, ketoacidosis and newâ€onset diabetes: Are there possible cause and effect relationships among them?. Diabetes, Obesity and Metabolism, 2020, 22, 2507-2508.	4.4	38
13	The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak. Diabetes Therapy, 2020, 11, 1191-1193.	2.5	7
14	COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be) Tj ETQqC) 0 0 rgBT 2.8	/Oygrlock 10
15	Insulin-Related Lipohypertrophy in Hemodialyzed Diabetic People: a Multicenter Observational Study and a Methodological Approach. Diabetes Therapy, 2019, 10, 1423-1433.	2.5	12
16	Considerations on lipoatrophic skin lesions far from insulin injection sites. Diabetes Research and Clinical Practice, 2018, 140, 347-350.	2.8	2
17	Insulin related lipodystrophic lesions and hypoglycemia: Double standards?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 813-818.	3.6	16
18	Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. Journal of Diabetes Research, 2018, 2018, 1-10.	2.3	13

#	Article	IF	CITATIONS
19	Cost saving effects of a short-term educational intervention entailing lower hypoglycaemic event rates in people with type 1 diabetes and lipo-hypertrophy. Diabetes Research and Clinical Practice, 2018, 143, 320-321.	2.8	12
20	The complex interplay between clinical and person-centered diabetes outcomes in the two genders. Health and Quality of Life Outcomes, 2017, 15, 41.	2.4	19
21	Lipodistrophy and Associated Risk Factors in Insulin-Treated People With Diabetes. International Journal of Endocrinology and Metabolism, 2016, 14, e33997.	1.0	8
22	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. Diabetes Care, 2016, 39, 1318-1328.	8.6	116
23	Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?. Diabetes Therapy, 2016, 7, 401-409.	2.5	45
24	A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. SpringerPlus, 2016, 5, 563.	1.2	68
25	Unexplained Hypoglycaemia and Large Glycaemic Variability: Skin Lipohypertrophy as a Predictive Sign. Sports and Exercise Medicine - Open Journal, 2016, 2, 24-32.	0.3	23
26	A Multicenter Italian Survey on Diabetes Care Units Reveals a Somewhat Slow Attitude in Treatment Guideline Implementation: Are We Dealing With Therapeutic Inertia?. Sports and Exercise Medicine - Open Journal, 2016, 2, 33-44.	0.3	5
27	Âlnsulin treatment of people with diabetes mellitus and chronic liver disease. Annals of Hepatology, 2016, 15, 287-8.	1.5	2
28	Metabolic effects of the association Berberis aristata/Silybum marianum: a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes. Nutrafoods, 2015, 14, 181-188.	0.5	6
29	Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetologica, 2015, 52, 845-853.	2.5	79
30	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	2.8	7
31	Correlates of diabetes-related distress in type 2 diabetes: Findings from the benchmarking network for clinical and humanistic outcomes in diabetes (BENCH-D) study. Journal of Psychosomatic Research, 2015, 79, 348-354.	2.6	73
32	Interplay among patient empowerment and clinical and person-centered outcomes in type 2 diabetes. The BENCH-D study. Patient Education and Counseling, 2015, 98, 1142-1149.	2.2	43
33	Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmacogenomics and Personalized Medicine, 2014, 7, 129.	0.7	15
34	Acarbose vs metformin for new-onset type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2014, 2, 104.	11.4	4
35	Different prevalence of metabolic control and chronic complication rate according to the time of referral to a diabetes care unit in the elderly. Acta Diabetologica, 2014, 51, 447-453.	2.5	6
36	Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetologica, 2011, 48, 121-125.	2.5	39

3

SANDRO GENTILE

#	Article	IF	CITATIONS
37	A randomized controlled trial of acarbose in hepatic encephalopathy. Clinical Gastroenterology and Hepatology, 2005, 3, 184-191.	4.4	116